Document is current
Any future updates will be listed below
-
Authors
Alvarez-Guaita, Anna
Cabrera-Serra, Julia
Perez-Gonzalez, Beatriz
Salcedo-Allende, Maria Teresa
Fuertes-Rioja, Lidia
Ramos-Perez, Lorena
Hernandez, Cristina
Simó, Rafael
Selva, David M. https://orcid.org/0000-0002-0333-5629
-
Funding
Funding for this research was provided by:
Agencia Estatal de Investigación (CPP2022-009831)
Agencia Estatal de Investigación (PTQ2021-011972)
Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (N/A)
European Regional Development Fund (N/A)
- License Information
-
More Information
Article History
Received: 4 November 2025
Accepted: 11 May 2026
First Online: 16 May 2026
Declarations
:
: All animal experimental procedures were reviewed and approved by the Animal Experimentation Ethics Committee of the Vall d’Hebron Research Institute (VHIR) and by the competent authority of the Generalitat de Catalunya, and were conducted in accordance with institutional guidelines, Spanish legislation (Real Decreto 53/2013), and European Union Directive 2010/63/EU on the protection of animals used for scientific purposes.
: DMS and RS are co-founders of Endolipid Therapeutics SL which is currently developing EDL6D for the treatment of MASLD and MASH. AAG and BPG are postdoctoral fellows of Endolipid Therapeutics SL, respectively. The rest of the authors declare they have no competing interest.
